US8247546B2 - Derivatives of acid polysaccharides - Google Patents
Derivatives of acid polysaccharides Download PDFInfo
- Publication number
- US8247546B2 US8247546B2 US12/521,307 US52130707A US8247546B2 US 8247546 B2 US8247546 B2 US 8247546B2 US 52130707 A US52130707 A US 52130707A US 8247546 B2 US8247546 B2 US 8247546B2
- Authority
- US
- United States
- Prior art keywords
- acid
- polysaccharides
- polysaccharide
- mmols
- autocrosslinked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
- C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/005—Crosslinking of cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0033—Xanthan, i.e. D-glucose, D-mannose and D-glucuronic acid units, saubstituted with acetate and pyruvate, with a main chain of (beta-1,4)-D-glucose units; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
Definitions
- This invention relates to acid autocrosslinked polysaccharides characterised by the concomitant presence of esters with non-polysaccharide carboxylic acids and esters between the acid groups of the same polysaccharide and the alcoholic groups of the repetitive units.
- carboxylated polysaccharides constitute raw materials of considerable interest for a wide variety of applications in the pharmaceutical and cosmetic industries.
- Some of them, such as hyaluronic acid (HA) are particularly valued for their high level of biotolerability and hydratability.
- HA hyaluronic acid
- the choice of material is often connected with cost aspects based on the value and importance of the final application.
- EP 0941253 describes the synthesis of HA derivatives with butyric anhydride in a basic environment, to obtain a product not crosslinked, having esterified hydroxy groups and which does not undergo any significant modification of its viscoelastic properties in aqueous solution.
- the process involves the use of the quaternary ammonium salt of HA and dimethylformamide (DMF) as aprotic solvent.
- DMF dimethylformamide
- EP 341745 teaches that autocrosslinking is obtained by “activating” the carboxyl by substituting the —OH group with an electron-attractor group X that allows the carbonyl carbon to be attached by a nucleophil (such as the —OH group of the monosaccharide units), with simultaneous detachment of X.
- the reagents described which are able to activate the carboxyl are the typical, well-known reagents that supply activated esters in peptide synthesis, such as water-soluble carbodiimides, carbonyldiimidazole, carbonyltriazole, N-hydroxysuccinimide, p-nitrophenol, p-nitrophenyltrifluoracetate, and salts of 2-halogen-N-alkylpyridine [T. Mukaiyama, Ang. Chem., 10 (18) 1979, 707-808]; the reaction is catalysed with triethylamine (TEA).
- TAA triethylamine
- the starting carboxylated polysaccharides are salified as tetrabutylammonium (TBA) salts soluble in aprotic solvents, such as dimethyl sulphoxide (DMSO), to obtain a single reaction phase.
- TAA tetrabutylammonium
- aprotic solvents such as dimethyl sulphoxide (DMSO)
- DMSO dimethyl sulphoxide
- the same patent also claims the use of sodium salts in the same aprotic organic solvents to conduct the same reaction.
- this salt is not soluble in solvents such as DMF or DMSO.
- FIG. 1 is a graph of a flow curve with zero-shear viscosity ranges vs shear stress with different cross-linking degrees according to examples 10, 13 and 14 and at the reference standard.
- FIG. 2 is a graph of the mechanical flow curves with different cross-linking degrees according to examples 10 and 13.
- FIGS. 3A-3C show results of compounds described in example 13 during a recovery test.
- the invention relates to natural or semisynthetic derivatives of acid polysaccharides wherein the alcoholic groups of the repetitive units occur, more or less extensively, in the form of esters with non-polysaccharide carboxylic acids, and the uronic acid groups are esterified, to a different extent, with other free alcoholic groups present in the polysaccharide chains.
- This latter type of bond induces autocrosslinking of the polysaccharide, thus influencing the viscoelastic behaviour of the end products;
- a suitable choice of acyl residue used to esterify the alcoholic hydroxyls enables other chemico-physical properties, such as hydrophilia/lipophilia and viscosity, to be modulated.
- the degree of autocrosslinking which is adjustable and reproducible, influences the characteristics of the final products (rigid gels, weak gels, products with increased viscosity).
- the derivatives according to the invention can be used as constituents of medical devices of various grades (I, II and III), such as injectable dermal fillers, post surgical antiadherence materials, devices for healing sores and wounds, etc., in slow-release galenical formulations, etc.).
- the rheological tests demonstrate that the derivatives according to the invention possess rheological properties characterised by viscoelastic behaviour which can be modulated according to the degree of autocrosslinking of the system, which ranges from a solution to that characteristic of a strong gel. It was found that the viscosity at low shear rates and the resistance to the force applied could be easily modulated. Finally, it was found that the polymer mixtures of the invention have a good ability to recover their viscoelastic properties after a rheological history of imposed stresses (pseudoplastic properties).
- the invention also relates to the process for the preparation of these derivatives comprising the reaction, in homogenous phase in the protic, polar solvent formamide, of the salt of a monovalent inorganic cation, such as sodium or potassium, of the selected carboxylated polysaccharide with an anhydride of an alkylcarboxylic acid, such as acetic, butyric, isobutyric, valeric, isovaleric or crotonic anhydride, etc., in the presence of a basic catalyst containing an atom of trisubstituted nitrogen, or an inorganic base such sodium or potassium salt of phosphoric acid or a salt of an organic acid with sodium or potassium.
- a basic catalyst containing an atom of trisubstituted nitrogen, or an inorganic base
- an inorganic base such sodium or potassium salt of phosphoric acid or a salt of an organic acid with sodium or potassium.
- the range of the hydroxyl residues involved in ester bonds with the acyl residue deriving from the anhydride is between 0.01 and 0.9 ⁇ N, where N is the number of hydroxyls in the repetitive unit.
- the formate ester formed by the formamide hydrolysis in the particular reaction environment may not be higher than 0.2.
- the starting polysaccharides can be in native form or differently modified according to the chemical functions present.
- Acid polysaccharides either in acid form or in the form of their inorganic salts, according to the invention are glycosaminoglycan selected from: hyaluronan, chondroitin sulphate, heparan sulphate, dermatan sulphate, keratan sulphate. Hyaluronic acid is particularly preferred.
- the molecular weight of the polysaccharides according to the invention can vary within a wide range, e.g. between 10 3 and 10 7 Daltons.
- the products according to the invention can be used as moisturising (dermo-) cosmetic agents, medical devices, intra-articular viscosupplementation agents, post surgical anti-adherence filling materials, and materials for covering wounds or sores.
- the products according to the invention can also be advantageously used as a carrier for the controlled release or absorption of active drugs.
- the 1 H NMR analyses are conducted in D 2 O with a Bruker Advance 400 spectrometer equipped with a 5 mm multinuclear probe with gradient z, at 300° K.
- the analyses also use diffusion-ordered experiments (DOSY: Diffusion Ordered Spectroscopy).
- the rheological tests were performed with a Rheostress Haake RS150 controlled-stress rotational rheometer.
- esters to the hydroxyls are analysed, again with 1 H NMR, exploiting the different resonance of the methyls and methylenes of the acyl residues bonded to the hydroxyls compared with the other polymer signals.
- These analysis are performed after addition of few microliters of a NaOD solution directly inside the NMR tube containing the swollen gel in D 2 O thus inducing full hydrolysis of both the crosslink esters and the esters with the non-saccharide acids.
- the gel was then transferred, slowly and under constant agitation, into 100 mL of an 0.2 M solution of NaCl, transferred to a dialysis membrane (cut-off 12,000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water. Finally, it was frozen and freeze-dried.
- the gel was then transferred, slowly and under constant agitation, into 70 mL of an 0.2 M solution of NaCl, and neutralised with KH 2 PO 4 . After approx. 16 hours' agitation, the system was transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water. Finally, it was frozen and freeze-dried.
- the gel was then transferred, slowly and under constant agitation, into 70 mL of an 0.2 M solution of NaCl, and then to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water. Finally, it was frozen and freeze-dried.
- reaction mixture was then transferred into 100 mL of an 0.2 M solution of NaCl, poured into a dialysis membrane (cut-off 12,000 D) and dialysed, firstly against an 0.2 M solution of NaCl and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 1.00 g of white lyophilisate was obtained.
- reaction mixture was then transferred into 100 mL of demineralised water, poured into a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an 0.2 M solution of NaCl and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.89 g of white lyophilisate was obtained.
- the gel was transferred into 350 mL of an 0.2 M solution of NaCl, and the mixture was transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and then exhaustively against demineralised water. Finally, the sample was frozen and freeze-dried, and 2.10 g of white lyophilisate was obtained.
- the gel was then transferred, slowly and under constant agitation, into 150 mL of an 0.2 M solution of NaCl, and neutralised with KH 2 PO 4 . It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water. Finally, it was frozen and freeze-dried.
- reaction mixture was then maintained under agitation for approximately 3 hours, and a further 320 ⁇ L of triethylamine (2.30 mmols) was added. After 2 hours, the gel was transferred into 100 mL of demineralised water and neutralised with KH 2 PO 4 . It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water.
- reaction mixture was then maintained under agitation for approximately 20 hours, and a further 550 ⁇ L of triethylamine (3.95 mmols) was added. After 6 hours, the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against ultrapure water.
- reaction mixture was then maintained under agitation for approximately 5 hours, and a further 280 ⁇ L of triethylamine (2.01 mmols) was added. After 16 hours, the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against ultrapure water.
- reaction mixture was then maintained under agitation for approximately 16 hours, and a further 311 ⁇ L of triethylamine (2.23 mmols) was added. After 6 hours 30 minutes the gel was transferred into approx. 40 mL of an 0.2 M solution of NaCl, transferred to a dialysis membrane (cut-off 12000 D), and exhaustively dialysed against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.90 g of white lyophilisate was obtained.
- reaction mixture was then maintained under agitation for approximately 16 hours, and a further 208 ⁇ L of triethylamine (1.49 mmols) was added. After 6 hours, the gel was transferred into 100 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against ultrapure water.
- reaction mixture was then maintained under agitation for 17 hours, and a further 320 ⁇ L of triethylamine (3.00 mmols) was added. After 6 hours 30 minutes the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against ultrapure water.
- reaction mixture was then maintained under agitation for 18 hours, and a further 740 ⁇ L of triethylamine (5.32 mmols) was added. After 6 hours, the system was transferred into 200 mL of demineralised water, neutralised with KH 2 PO 4 , transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against water.
- reaction mixture was then maintained under mechanical stirring for approximately 30 minutes, and 2 ml of a formamide solution containing 1.21 g of potassium acetate (12.3 mmols) were added. After 16 hours, the gel was transferred into 200 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against ultrapure water.
- reaction mixture was then maintained under agitation for 19 hours, and a further 143 ⁇ L of triethylamine (1.03 mmols) was added. After 41 ⁇ 2 hours the system was transferred into 100 mL of an 0.2 M solution of NaCl, and neutralised with KH 2 PO 4 . It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCl and secondly against demineralised water.
- the reaction mixture was maintained under agitation for 18 hours, and a further 320 ⁇ L of triethylamine (2.30 mmols) was added. After 7 hours 30 minutes the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an aqueous solution of 0.2 M NaCl and secondly against ultrapure water.
- the reaction mixture was maintained under agitation for 16 hours, and a further 167 ⁇ L of triethylamine (1.20 mmols) was added. After 6 hours, the gel was transferred into 100 mL of demineralised water and neutralised with KH 2 PO 4 , and 2.5 g of NaCl was added. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed against water.
- rheological measurements we used a controlled stress rheometer, a mechanical spectrometer capable of subjecting a sample to either a dynamic (sinusoidal) or steady (linear) shear stress.
- a magnetic field generates a torque on the upper mobile measurement sensor, air-bearing supported, that converts in stress applied on the sample.
- the resultant rotational degree and speed of the mobile measurement system are detected by an optical laser system, and thus the strain expended by the sample in response to the shear stress, and the shear rate are estimated.
- the rheometer used was a Rheostress Haake RS150, equipped with rough or smooth surfaces sensors useful for all types of measurements in rotation and oscillation, respectively for high or low structured systems. All measurements were done at 25° C., using a specific thermocontroller.
- FIG. 1 shows how zero-shear viscosity ranges from 0.01 Pa*s to 100.000 Pa*s by increasing cross-link degree, and how qualitative and quantitative changes occurred on rheological properties over the wide shear stress range.
- Compounds having a low cross-linking degree behave like solutions while the more crosslinked they are, the more plastic they become. Infact, their profiles range from close to Newtonian to apparently plastic behaviour, characterized by a dramatic viscosity drop of many orders of magnitude over a narrow shear stress range.
- FIG. 2 shows the mechanical spectra of different systems. No mechanical spectra could be recorded for the compounds having the lowest crosslinking degree indicated as reference and example 14, since a linear viscoelasticity field could not be recognised.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
-
- flow curves: continuous/steady state measurements of viscosity over a wide range of shear rate or shear stress;
- stress and frequency sweep: dynamic measurements (oscillation) for the determination of samples viscoelastic behaviour. In particular stress sweep is done in order to individuate the linear viscoelastic range extension, and thus the critical strain value for the linear/non linear transition. Frequency sweep gives systems' mechanical spectra, that are the storage modulus G′ and the loss modulus G″ profiles over a wide range of frequency, in the linear viscoelasticity field.
- recovery sweep: to evaluate the viscoelastic properties recovery of a sample undergone a certain rheological history: three measurement cycles are applied, each one composed by oscillatory steps, under constant amplitude and frequency of strain, before and after the application of a constant shear rate (respectively 100 s−1, 100 s−1, 500 s−1 during each cycle)
| Shear viscosity | Storage | Loss | ||||
| Example | Shear viscosity | ηat shear rate | modules G′ | modules G″ | D.S. | D.S. |
| no. | η0 [Pa · s] | 700 s−1 [Pa · s] | at 1 Hz [Pa] | at 1 Hz [Pa] | ester | Links |
| linear native | 0.1 | 0.05 | np | np | 0 | 0 |
| linear butyrate | 0.008 | 0.007 | np | np | 0.07 | 0 |
| ester | ||||||
| 4 | 10.000, 0 | 0.09 | 60 | 21 | 0.12 | 0.03 |
| 5 | 0.9 | 0.05 | 0.8 | 1.8 | 0.05 | 0.01 |
| 6 | 8.000, 0 | 0.2 | 32 | 12 | 0.08 | 0.03 |
| 10 | 87.000, 0 | 0.10 | 165 | 38 | 0.15 | 0.05 |
| 13 | 30.0 | 0.07 | 3.1 | 3.3 | 0.06 | 0.02 |
| 14 | 0.06 | 0.01 | np | np | 0.06 | 0.01 |
| 15(1) | 180.000, 0 | 15 | 777.3 | 173.8 | 0.06 | 0.01 |
| (1)The gel was swollen in a 0.9% NaCl at pH = 5.5 water solution; the polymer concentration was 2% w/w. | ||||||
- (1) The gel was swollen in a 0.9% NaCl at pH=5.5 water solution; the polymer concentration was 2% w/w.
Claims (15)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06425874.2 | 2006-12-29 | ||
| EP06425874A EP1942117A1 (en) | 2006-12-29 | 2006-12-29 | Derivatives of acid polysaccharides |
| EP06425874 | 2006-12-29 | ||
| PCT/IB2007/003973 WO2008081255A1 (en) | 2006-12-29 | 2007-12-18 | Derivatives of acid polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20100292459A1 US20100292459A1 (en) | 2010-11-18 |
| US8247546B2 true US8247546B2 (en) | 2012-08-21 |
Family
ID=37904391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/521,307 Active 2028-10-17 US8247546B2 (en) | 2006-12-29 | 2007-12-18 | Derivatives of acid polysaccharides |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8247546B2 (en) |
| EP (2) | EP1942117A1 (en) |
| JP (1) | JP5372773B2 (en) |
| AU (1) | AU2007341078B2 (en) |
| CA (1) | CA2673947C (en) |
| ES (1) | ES2633712T3 (en) |
| PL (1) | PL2097457T3 (en) |
| PT (1) | PT2097457T (en) |
| WO (1) | WO2008081255A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015074632A1 (en) | 2013-11-21 | 2015-05-28 | Contipro Biotech S R.O. | Nanofibers containing photocurable ester derivative of hyaluronic acid or its salt, photocured nanofibers, method of synthesis thereof, preparation containing photocured nanofibers and use thereof |
| US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
| US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
| US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
| US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
| US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
| US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
| US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
| US20230295351A1 (en) * | 2021-04-21 | 2023-09-21 | Shandong Focusfreda Biotech Co., Ltd | Preparation method for acetylated sodium hyaluronate |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20072237A1 (en) * | 2007-11-27 | 2009-05-28 | Sigea Srl | MIXED BUTIRRIC-FORMAL ESTERS OF ACID POLYSACCHARIDES, THEIR PREPARATION AND USE AS DERMOCOSMETICS |
| KR101078302B1 (en) * | 2008-05-29 | 2011-10-31 | (주)프로넥스 | Drug Delivery System |
| ITTO20110428A1 (en) * | 2011-05-13 | 2012-11-14 | Rottapharm Spa | ESTERS OF HYALURONIC ACID, THEIR PREPARATION AND USE IN DERMATOLOGY |
| FR2983483B1 (en) * | 2011-12-02 | 2014-11-14 | Vivacy Lab | PROCESS FOR SIMULTANEOUS SUBSTITUTION AND RETICULATION OF A POLYSACCHARIDE VIA ITS HYDROXYL FUNCTIONS |
| PT3245233T (en) * | 2015-01-13 | 2019-01-16 | Bmg Pharma S P A | Process in water for the preparation of butyric esters of hyaluronic acid sodium salt |
| CN110891611B (en) | 2017-03-22 | 2024-03-29 | 阿森迪斯制药公司 | Hydrogel crosslinked hyaluronic acid prodrug compositions and methods |
| CN110732037B (en) | 2018-07-20 | 2023-05-26 | 广州倍绣生物技术有限公司 | Hemostatic paste and preparation method thereof |
| CN110467691A (en) * | 2019-09-23 | 2019-11-19 | 山东银河生物科技有限公司 | A method of preparing acetylation hyaluronic acid |
| IT201900021693A1 (en) * | 2019-11-20 | 2021-05-20 | Bmg Pharma S P A | BUTYRATED OR BUTYRATED DERIVATIVES AND FORMS OF CROSS-LINKED HYALURONIC ACID AND THEIR CROSS-LINKING PROCEDURE |
| CN110981991B (en) * | 2019-12-24 | 2021-12-07 | 江苏诚信药业有限公司 | Preparation method of acetylated hyaluronate |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2589226A (en) | 1946-11-22 | 1952-03-18 | Us Agriculture | Acylation of polysaccharides in formamide |
| US3758577A (en) * | 1971-11-01 | 1973-09-11 | Goodrich Co B F | Stabilization of dimethylformamide |
| US4152170A (en) | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
| US4675393A (en) * | 1982-04-02 | 1987-06-23 | Lever Brothers Company | Process for preparing glucose penta-acetate and xylose tetra-acetate |
| EP0341745A1 (en) * | 1988-05-13 | 1989-11-15 | FIDIA S.p.A. | Crosslinked carboxy polysaccharides |
| US5221739A (en) * | 1992-01-09 | 1993-06-22 | Eli Lilly And Company | Acetylation of 3-hydroxymethyl cephalosporins |
| FR2752843A1 (en) | 1996-08-30 | 1998-03-06 | Sod Conseils Rech Applic | CROSS-LINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION SUPPORT |
| US6410044B1 (en) | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
| US6552184B1 (en) * | 1999-04-08 | 2003-04-22 | Fidia Advanced Biopolymer S.R.L. | Process for the preparation of autocrosslinked compounds of hyaluronic acid and the derivatives thereof by the supercritical antisolvent technique |
| WO2005092929A1 (en) * | 2004-03-29 | 2005-10-06 | Sintofarm S.P.A. | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51149883A (en) * | 1975-06-19 | 1976-12-23 | Sumitomo Chem Co Ltd | Hydrophilic gel |
| IT1198449B (en) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
| IT1286510B1 (en) * | 1996-11-29 | 1998-07-15 | Cooperativa Centro Ricerche Po | BUTYRIC ESTERS WITH ANTI-PROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| US6007833A (en) * | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
-
2006
- 2006-12-29 EP EP06425874A patent/EP1942117A1/en not_active Withdrawn
-
2007
- 2007-12-18 CA CA2673947A patent/CA2673947C/en active Active
- 2007-12-18 US US12/521,307 patent/US8247546B2/en active Active
- 2007-12-18 PT PT78590957T patent/PT2097457T/en unknown
- 2007-12-18 PL PL07859095T patent/PL2097457T3/en unknown
- 2007-12-18 AU AU2007341078A patent/AU2007341078B2/en active Active
- 2007-12-18 ES ES07859095.7T patent/ES2633712T3/en active Active
- 2007-12-18 JP JP2009543534A patent/JP5372773B2/en active Active
- 2007-12-18 WO PCT/IB2007/003973 patent/WO2008081255A1/en not_active Ceased
- 2007-12-18 EP EP07859095.7A patent/EP2097457B1/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2589226A (en) | 1946-11-22 | 1952-03-18 | Us Agriculture | Acylation of polysaccharides in formamide |
| US3758577A (en) * | 1971-11-01 | 1973-09-11 | Goodrich Co B F | Stabilization of dimethylformamide |
| US4152170A (en) | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
| US4675393A (en) * | 1982-04-02 | 1987-06-23 | Lever Brothers Company | Process for preparing glucose penta-acetate and xylose tetra-acetate |
| EP0341745A1 (en) * | 1988-05-13 | 1989-11-15 | FIDIA S.p.A. | Crosslinked carboxy polysaccharides |
| US5221739A (en) * | 1992-01-09 | 1993-06-22 | Eli Lilly And Company | Acetylation of 3-hydroxymethyl cephalosporins |
| FR2752843A1 (en) | 1996-08-30 | 1998-03-06 | Sod Conseils Rech Applic | CROSS-LINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION SUPPORT |
| US6410044B1 (en) | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
| US6552184B1 (en) * | 1999-04-08 | 2003-04-22 | Fidia Advanced Biopolymer S.R.L. | Process for the preparation of autocrosslinked compounds of hyaluronic acid and the derivatives thereof by the supercritical antisolvent technique |
| WO2005092929A1 (en) * | 2004-03-29 | 2005-10-06 | Sintofarm S.P.A. | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
| WO2015074632A1 (en) | 2013-11-21 | 2015-05-28 | Contipro Biotech S R.O. | Nanofibers containing photocurable ester derivative of hyaluronic acid or its salt, photocured nanofibers, method of synthesis thereof, preparation containing photocured nanofibers and use thereof |
| US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
| US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
| US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
| US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
| US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
| US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
| US20230295351A1 (en) * | 2021-04-21 | 2023-09-21 | Shandong Focusfreda Biotech Co., Ltd | Preparation method for acetylated sodium hyaluronate |
| US12435162B2 (en) * | 2021-04-21 | 2025-10-07 | Shandong Focusfreda Biotech Co., Ltd | Preparation method for acetylated sodium hyaluronate |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292459A1 (en) | 2010-11-18 |
| EP1942117A1 (en) | 2008-07-09 |
| WO2008081255A1 (en) | 2008-07-10 |
| CA2673947A1 (en) | 2008-07-10 |
| JP5372773B2 (en) | 2013-12-18 |
| ES2633712T3 (en) | 2017-09-25 |
| EP2097457A1 (en) | 2009-09-09 |
| PT2097457T (en) | 2017-07-20 |
| CA2673947C (en) | 2016-02-23 |
| AU2007341078A1 (en) | 2008-07-10 |
| AU2007341078B2 (en) | 2013-03-07 |
| JP2010514878A (en) | 2010-05-06 |
| EP2097457B1 (en) | 2017-07-12 |
| PL2097457T3 (en) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8247546B2 (en) | Derivatives of acid polysaccharides | |
| JP5661470B2 (en) | Polysaccharide derivatives of lipoic acid, their preparation, use as cosmetics for skin and medical devices | |
| Kono et al. | Preparation and characterization of guar gum hydrogels as carrier materials for controlled protein drug delivery | |
| Gómez-Mascaraque et al. | Oxidized dextrins as alternative crosslinking agents for polysaccharides: application to hydrogels of agarose–chitosan | |
| RU2230073C2 (en) | Method for cross-linking carboxylated polysaccharides | |
| US20070053987A1 (en) | Cross-linked polysacharide and protein matrices and methods for their preparation | |
| Agnello et al. | Synthesis, mechanical and thermal rheological properties of new gellan gum derivatives | |
| JP5372774B2 (en) | Polysaccharide derivatives containing citric acid | |
| JP4958368B2 (en) | Cross-linked hyaluronic acid | |
| JP7747335B2 (en) | Crosslinked hyaluronic acid butyrate or butyrate-formate derivatives and method for crosslinking same | |
| Putri et al. | Rheological and Self-Healing Behavior of Hydrogels Synthesized from L-Lysine-Functionalized Alginate Dialdehyde. Polymers 2023, 15, 1010 | |
| Ying et al. | Relationships between the molecular structure and moisture-absorption and moisture-retention abilities of succinyl chitosan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SIGEA S.R.L., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STUCCHI, LUCA;BOSCO, MARCO;GIANNI, RITA;AND OTHERS;REEL/FRAME:022901/0366 Effective date: 20090615 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |
|
| AS | Assignment |
Owner name: BMG PHARMA S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIGEA SRL;REEL/FRAME:072433/0743 Effective date: 20180611 Owner name: BMG PHARMA S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:SIGEA SRL;REEL/FRAME:072433/0743 Effective date: 20180611 |